close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fate Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE NBIX
News headline image
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics to Present at Upcoming Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
Tickers FATE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.